EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57

Abstract

SECUKINUMAB IN PSORIASIS: RESULTS FROM A SINGLE-CENTER DATABASE

Sanjid Ahammed Eramasam Veedu, Wu Jianbo and Xie Jun*

ABSTRACT

Introduction: Due to the blanket immune damp down of conventional psoriasis therapies, secukinumab; a targeted IL-17 receptor inhibitor was introduced to manage moderate to severe psoriasis. This study aimed to ascertain the efficacy and safety of secukinumab either alone or in combination with topical agents, for managing psoriasis. Methods: A retrospective observational study was conducted at Zhongnan Hospital of Wuhan University from October 2021 to January 2023. Secukinumab therapy was analyzed in 91 moderate to severe psoriasis patients. Data was analyzes in SPSS using independent sample t-test and Parsons’s Chi-square of Fischer’s exact test. Results: A total of 91 psoriasis patients were analyzed; 69 (75.8%) males, and a mean (±SD) age of 45.8±15.7 years. Mean (±SD) baseline PASI score was 13.12±6.6. At 48 week, response to treatment as measured by PASI 50, 75, and 90 response rates were 28.6%, 7.1% and 3.6% for secukinumab monotherapy and 44.4%, 6.7% and 6.3% for secukinumab & topical combination therapy respectively. Only PASI 50 was statistically significant between the two groups. This finding suggest that combination of secukinumab & topical therapy was more effective than monotherapy. At 48 weeks, the PASI 50, 75, and 90 response rates were 13.1%, 4.7%, and 2.4% in biologics naïve patients versus 14.3%, 0%, and 0% in non-biologics naïve ones respectively, suggesting better response in biologics naïve patients. Conclusion: Combination of secukinumab & topical agent was safe and more effective than secukinumab monotherapy. Biologics naïve patients respond better to secukinumab than those pre-exposed to biologics.

Keywords: Secukinumab, psoriasis, biologic treatment, efficacy, safety.


[Full Text Article] [Download Certificate]

Citation

  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44

INDEXING

NEWS & UPDATION

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • EJPMR: FEBRUARY ISSUE PUBLISHED

    FEBRUARY 2024 issue has been successfully launched on 1 FEBRUARY 2024.

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 February 2024 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia